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Abstract
The prevailing hypothesis of HIV budding posits that the viral Gag protein drives budding, and that the Gag p6 peptide
plays an essential role by recruiting host-cell budding factors to sites of HIV assembly. HIV also expresses a second Gag
protein, p160 Gag-Pol, which lacks p6 and fails to bud from cells, consistent with the prevailing hypothesis of HIV budding.
However, we show here that the severe budding defect of Gag-Pol is not caused by the absence of p6, but rather, by the
presence of Pol. Specifically, we show that (i) the budding defect of Gag-Pol is unaffected by loss of HIV protease activity
and is therefore an intrinsic property of the Gag-Pol polyprotein, (ii) the N-terminal 433 amino acids of Gag and Gag-Pol are
sufficient to drive virus budding even though they lack p6, (iii) the severe budding defect of Gag-Pol is caused by a
dominant, cis-acting inhibitor of budding in the HIV Pol domain, and (iv) Gag-Pol inhibits Gag and virus budding in trans,
even at normal levels of Gag and Gag-Pol expression. These and other data support an alternative hypothesis of HIV
budding as a process that is mediated by the normal, non-viral pathway of exosome/microvesicle biogenesis.
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Introduction
Retrovirus budding is an important but incompletely under-
stood process, with relevance to both the viral lifecycle [1,2,3] and
the biogenesis of secreted vesicles (e.g. exosomes and microvesicles
(EMVs) [4,5]). Early studies on HIV budding demonstrated that
loss of the Gag p6 domain caused a severe defect in virus budding
[6], and that mutation of short peptide motifs within p6 could also
cause a similar phenotype [7]. These motifs (PTAP, YPxL) bind
directly to components of the endosomal sorting complexes required for
transport (ESCRT) machinery, which is required for cytokinesis,
biogenesis of multivesicular bodies, autophagy, and also for HIV
budding [8,9,10]. Based on these results, it has been proposed that
the p6 domain represents the primary budding information in
HIV [1,2]. This hypothesis is also consistent with the current
model of outward vesicle budding (outward=away from the
cytoplasm), which posits a central role for the ESCRT machinery
in cargo selection and vesicle budding [5,11,12].
This hypothesis of HIV budding is consistent with some lines of
evidence but difficult to reconcile with others. In particular, Freed
and others observed that p6-deficient HIV shows ‘no defect in particle
release’ from human T-cells [13,14], undermining the idea that p6
plays a critical role in budding. More recently, we established that
plasma membrane (PM)-binding and higher-order oligomerization
are the primary budding signals in HIV Gag, and are located in its
matrix (MA), capsid (CA), and nucleocapsid (NC) domains
[14,15]. As for the severe budding defect seen for p6-deficient
and PTAP-deficient forms of HIV in 293T and certain other cell
types [6,13], this appears to be caused by the activation of an
inhibitory budding signal (IBS) in the SP2 domain of Gag [15],
rather than the loss of positive budding information. Taken
together, these observations support an alternative hypothesis in
which retroviruses bud by the normal, non-viral pathway of EMV
biogenesis [4].
EMVs are small, membrane-bound vesicles secreted by a wide
array of animal cells and mediate the release of specific subsets of
proteins, lipids, carbohydrates, and nucleic acids [16,17]. The
EMV-based hypothesis of HIV budding is also supported by (i)
similarities between the host-cell proteins, lipids, and carbohy-
drates that are present on HIV particles and on EMVs [4,18,19],
(ii) the fact that EMVs and HIV particles bud from the same
locations of human T-cells, macrophages, and polarized leukocytes
[14,19,20,21,22,23,24], and (iii) the observation that PM-binding
and higher-order oligomerization target diverse proteins to both
HIV particles and EMVs [14,15,22].
Although the existing data favor an EMV-based hypothesis of
HIV budding, it is unclear whether this model can explain the
severe budding defect reported for the HIV Gag-Pol protein
[25,26,27]. HIV expresses Gag and Gag-Pol from the same
mRNA. Both proteins share the identical N-terminal 433 amino
acids but differ at their C-terminus. In p55 Gag, the shared N-
terminal 433 amino acids is followed by the 16 amino acid-long
spacer peptide 2 (SP2) and the 52 amino acid-long p6 peptide. In
p160 Gag-Pol, which lacks SP2 and p6, the shared N-terminal 433
amino acids are instead followed by the 1003 amino acid-long Pol
domain (p160 Gag-Pol is generated by a 21 ribosomal frameshift
at codon 433 of the Gag ORF). Under the prevailing hypothesis of
HIV budding, Gag should bud from cells and Gag-Pol should not,
because the former protein possesses p6 and the latter does not.
However, we show here that the severe budding defect of Gag-Pol
is caused by the presence of a dominant, cis-acting inhibitor of
budding in HIV Pol, and not by the absence of p6. Furthermore,
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29421we show that the N-terminal 433 amino acids of HIV Gag-Pol are
sufficient to bud from cells, supporting the hypothesis that HIV
budding is mediated by the EMV biogenesis pathway.
Results
Protease does not mediate the budding defect of HIV
Gag-Pol
HIV expresses its Gag and Gag-Pol proteins from a single
mRNA, with Gag being the primary translation product and Gag-
Pol being generated by a 21 ribosomal frameshift at codon 433 of
the Gag ORF (Fig. 1A). As a result, Gag and Gag-Pol share the
same N-terminal 433 amino acids (the MA, CA, and NC domains)
but have different C-terminal domains. In Gag, this divergent
sequence consists of the SP2 and p6 peptides, while in Gag-Pol it
corresponds to the 1003 amino acids of Pol, itself comprised of
transframe (TF), protease (PR), reverse transcriptase (RT), p15,
and integrase (IN) domains [28].
It has been established that fusing the Gag and Pol reading
frames in an HIV provirus (at the site of the Gag-Pol translational
frameshift) results in much higher levels of Gag-Pol expression,
prevents the synthesis of Gag, and causes a severe defect in HIV
budding [25,26,27]. Elevated expression of HIV Gag-Pol also
leads to elevated expression of PR activity, a known inhibitor of
HIV budding, as well as to the extensive cleavage of cell-associated
Gag-Pol. This raises the possibility that the budding defect
observed for Gag-Pol virus reflects the elevated, unregulated, and/
or premature PR activity, rather than the intrinsic budding activity
of the full-length p160 Gag-Pol protein [25,26,27]. To assess the
role of PR activity in the budding defect of Gag-Pol virus we
compared the budding of control HIV (NL4-3*, our designation
[15] for NL4-3-DE-GFP, an ENV-deficient form of NL4-3 used
for quantitative assays of HIV function [29]) to that of a derivative
in which the Gag and Pol reading frames were fused (NL4-3*/
Gag-Pol
fuse), and also to that of a matched provirus in which PR
was mutationally inactivated (NL4-3*/Gag-Pol
fuse/PR
D25A) [7].
Figure 1. Gag-Pol does not bud from 293T cells. (A) Line diagram of the p55 HIV Gag and p160 HIV Gag-Pol proteins, as well as the protein
product of the NL4-3*/Gag-Pol
fuse/PR
D25A provirus. The full-length p55 Gag and p160 Gag-Pol proteins contain a shared N-terminal 433 amino acids
containing the MA, CA, and NC domains but different C-terminal extensions, SP2 and p6 in the case of Gag, and Pol in the case of Gag-Pol. (B) Anti-
Gag immunoblots of cell and virus lysates generated from 293T cells transfected with the proviruses NL4-3*, NL4-3*/Gag-Pol
fuse/PR
D25A and NL4-3*/
Gag-Pol
fuse. Bar graph shows the average+/21 standard deviation from three trials. The three stars refers to a p value of less than 0.0005.
doi:10.1371/journal.pone.0029421.g001
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proviruses NL4-3*, NL4-3*/Gag-Pol
fuse, and NL4-3*/Gag-Pol-
fuse/PR
D25A, incubated for two days, and then cells and virus
particles were collected (viruses were purified by differential
centrifugation from the tissue culture supernantant). Cell and virus
samples were then lysed in SDS-PAGE sample buffer and the
lysates were processed for immunoblot using antibodies specific for
the CA domain of Gag-Pol (Fig. 1). These virus budding
experiments revealed that NL4-3* budded efficiently from 293T
cells, as expected. However, we detected very little budding for
either NL4-3*/Gag-Pol
fuse (0% of control; n=3) or NL4-3*/Gag-
Pol
fuse/PR
D25A (0.2+/20.3% of control; n=3; p=4.3610
26)
(Fig. 1A,B). These results confirm that the Gag-Pol protein has a
severe defect in budding, and also demonstrate that the HIV
protease, PR, does not cause the budding defect of Gag-Pol.
The budding defect of Gag-Pol is not caused by its lack
of p6 sequences
To test whether the budding defect of p160 Gag-Pol is due to
the absence of p6 sequences or whether it might be caused by
some other difference between it and p55 Gag, we followed the
budding of another HIV mutant, NL4-3*/SP2
F1ter. This virus
replaces the first codon of the SP2 domain (Phe1) with a nonsense
mutation, expresses only the N-terminal 433 amino acids that are
shared by the Gag and Gag-Pol proteins, and lacks the SP2 and
p6 domains of p55 Gag and the Pol domain of p160 Gag-Pol.
Moreover, we simplified the analysis of its budding by comparing
the release of NL4-3*/SP2
F1ter to that of NL4-3*/TF
ter,a nH I V
mutant that expresses only p55 Gag (Fig. 1A; the TF
ter mutation
has a nonsense mutation in the Pol ORF just downstream of the
ribosomal frameshift [28]), lacks PR activity, and therefore
doesn’t cleave Gag into smaller polypeptides. 293T cells were
transfected with NL4-3*/TF
ter,N L 4 - 3 * / G a g - P o l
fuse/PR
D25A,
and NL4-3*/SP2
F1ter, cell and virus lysates were collected, and
these were processed for immunoblot using anti-CA antibody
(Figs. 2,3). NL4-3*/SP2
F1ter budded quite well, 73+/29%
relative to NL4-3*/TF
ter (n=3; p=0.033). This was ,70-fold
more budding than seen for NL4-3*/Gag-Pol
fuse/PR
D25A,w h i c h
budded at only 1.1+/22% of control (n=3; p=1.2610
24).
These data demonstrate that the budding defect of Gag-Pol is
caused by the presence of Pol sequences and not by the absence
of p6 sequences.
Figure 2. Relevant DNA sequences of control and mutant HIV proviruses. (A) Short segments of the NL4-3* DNA sequence and their
alteration in the proviruses NL4-3*/Gag-Pol
fuse, NL4-3*/Gag-Pol
fuse/PR
D25A, NL4-3*/SP2
F1ter, and NL4-3*/TF
ter, respectively. (B) DNA sequence
fragments of NL4-3* in the vicinity of the PR
D25A and the PR
P1ter mutations in NL4-3*/Gag-Pol
fuse/PR
D25A and NL4-3*/Gag-Pol
fuse/PR
P1ter, respectivel.
(C) DNA sequence of the PR
D25A and the RT
P1ter mutations in NL4-3*/Gag-Pol
fuse/PR
D25A and NL4-3*/Gag-Pol
fuse/PR
D25A/RT
P1ter. (D) DNA sequence
alignments in the vicinity of the PR
D25A and the p15
Y1ter mutations in NL4-3*/Gag-Pol
fuse/PR
D25A and NL4-3*/Gag-Pol
fuse/PR
D25A/p15
Y1ter. (E) DNA
sequences surrounding the PR
D25A and the IN
F1ter mutations in NL4-3*/Gag-Pol
fuse/PR
D25A and NL4-3*/Gag-Pol
fuse/PR
D25A/IN
F1ter.
doi:10.1371/journal.pone.0029421.g002
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PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e29421We next explored the regions of Pol that contribute to the
budding defect of p160 Gag-Pol. For this, we generated derivatives
of NL4-3*/Gag-Pol
fuse that contained stop codons immediately
after the TF, PR, RT, and p15 domains of the Pol ORF (Fig. 3A).
Following the expression of these proviruses in 293T cells, cell and
EMV lysates were prepared and examined by immunoblot
(Fig. 3B). NL4-3*/Gag-Pol
fuse/PR
P1ter, which expressed a Gag-
Pol protein containing the first 433 amino acids of Gag and the TF
domain of Pol, budded at 68+/221% the level of NL4-3*/TF
ter
(n=3; p=0.12). This is essentially the same level of budding that
we observed for NL4-3*/SP2
F1ter, which expresses just the MA-
CA-SP1-NC domains of Gag. NL4-3*/Gag-Pol
fuse/PR
D25A/
RT
P1ter is designed to express a longer Gag-Pol protein consisting
of the MA, CA, NC, TF, and PR domains. It budded a bit less,
26+/26% relative to NL4-3*/TF
ter (n=3; p=2.3610
25).
Inclusion of the RT domain caused an even larger decrease in
HIV budding, to 4.3+/23% (n=3; p=3.6610
24) for NL4-3*/
Gag-Pol
fuse/PR
D25A/p15
Y1ter and to 3.9+/24% (n=3;
p=5.1610
24) for NL4-3*/Gag-Pol
fuse/PR
D25A/IN
F1ter. These
data demonstrate that the severe budding defect of Gag-Pol is
caused primarily by sequences within the RT domain of Pol, and
perhaps also by sequences within its PR domain.
Gag-Pol inhibits HIV budding in trans
The inhibitory effect of Pol on Gag and HIV budding, coupled
with the known co-assembly of Gag and Gag-Pol polyproteins
[26], raises the possibility that Gag-Pol might also inhibit the
budding of HIV in trans. To test this hypothesis we transfected
293T cells with a mix of (i) NL4-3*/TF
ter, which expresses only
Gag and no Gag-Pol, and (ii) NL4-3*/Gag-Pol
fuse/PR
D25A, which
expresses Gag-Pol but no Gag (Fig. 4A). Two days later we
collected cell and virus lysates and processed each by immunoblot
using antibodies specific for the CA domain of the Gag and Gag-
Pol proteins (Fig. 4B). These experiments revealed that expression
of PR-deficient Gag-Pol had a dominant, inhibitory effect on HIV
budding in trans. Peak inhibition, an ,20-fold decrease (5.4+/
23%; n=3; p=2.7610
24), was observed at the highest ratio of
Gag-Pol:Gag provirus, 7.5:1. Significant inhibition of HIV
budding was also observed at the lower Gag-Pol:Gag ratios of
5:1 (11+/27%; n=3; p=2.3610
23) and 3:1 (32+/27%; n=3;
p=3.7610
23). We failed to detect significant inhibition at Gag-
Pol:Gag ratios of 1:1 (92+/214%; n=3; p=0.42) or 1:2 (99+/
29%; n=3; p=0.97).
HIV Gag-Pol inhibits HIV budding
The inhibitory effect of Gag-Pol on HIV budding raised the
possibility that Gag-Pol normally inhibits budding. To test this
possibility, we compared the budding of NL4-3*, which expresses
Gag and Gag-Pol at their normal levels and ratio, to that of NL4-
3*/TF
ter, which expresses Gag but no Gag-Pol [15]. 293T cells
were transfected with the two proviruses, cell and virus lysates
were collected, and each was processed for immunoblot using
antibodies specific for the Gag CA domain (Fig. 4C). The
budding of NL4-3*/TF
ter was 182+/219% (n=3; p=0.018) of
that we observed for NL4-3*. These results demonstrate that
expression of Gag-Pol inhibits HIV budding even at its normal,
low level of expression [28].
Discussion
Virus budding is a critical step in the HIV lifecycle. The
prevailing paradigm of HIV budding proposes that the p6 domain
of Gag plays a critical role, recruiting the ESCRT machinery to
sites of virus assembly where it then catalyzes virion budding [1,2].
This hypothesis is consistent with a wide array of empirical
observations, including the severe budding defect of HIV Gag-Pol,
which lacks the p6 domain. However, we show here that the
severe budding defect of HIV Gag-Pol cannot be explained by the
absence of p6. This conclusion is based primarily on the fact that
NL4-3*/SP2
F1ter budded normally, even though it only expresses
the first 433 amino acids of Gag (the MA, CA, SP1, and NC
domains) and lacks the p6 domain. Although this observation is
inconsistent with the prevailing model of the p6 domain in HIV
budding, it supports the alternative hypothesis that HIV budding
follows the normal, non-viral pathway of EMV biogenesis
[4,14,15,19,20,24].
Our data also demonstrate that Pol acts in cis to block the
budding of Gag-Pol. Furthermore, the severe budding defect of
PR-deficient Gag-Pol means that the Pol polypeptide itself
functions as an inhibitory budding element. This is significant,
as it has been previously hypothesized that the budding defect of
Gag-Pol might be caused by its overexpression of PR activity
[25,26,27]. The inhibitory effect of Pol on budding is not without
precedent, as HIV has another cis-acting inhibitor of budding, the
IBS that it located in the SP2 domain of Gag [15]. The cis-acting
inhibitor in Pol mapped primarily to its RT domain, though the
PR domain might also play a role. Regardless of its precise
location, our data indicates that the inhibitory budding element in
Pol also impairs the budding of HIV in trans. This was most
obvious in our two virus expression experiments, where high levels
of Gag-Pol effectively blocked HIV budding. However, Pol also
had an inhibitory effect on HIV budding in the context of our
control HIV provirus, where Gag-Pol expression caused an ,2-
fold reduction in HIV budding. Taken together, these data
reinforce the concept that HIV budding is controlled by both
positive and inhibitory budding signals, some that are shared with
the non-viral EMV biogenesis pathway, and some that are unique
to HIV [14,15].
Our observations also raise the question of why HIV possesses
inhibitory budding signals like the one detected here in Pol, and
the IBS we identified previously in the SP2 domain of Gag [15].
Currently, we do not have a mechanistic model for why HIV
would benefit from the presence of an IBS. Given the central role
of budding in the HIV lifecycle, the existence of IBSs within the
Gag and Gag-Pol proteins seem incongruous, and there is clearly a
need for further research to identify the functional significance of
these elements in the HIV lifecycle. However, it is clear that
inhibitory budding signals do exist within HIV, that they can have
a pronounced impact on HIV budding, and that their discovery
Figure 3. Relative budding of different C-terminal truncation mutations of Gag-Pol. (A) Line diagram of proteins expressed by the
proviruses NL4-3*/TF
ter (Gag(p55)), NL4-3*/Gag-Pol
fuse/PR
D25A (Gag-Pol(PR-D25A)), NL4-3*/SP2
F1ter (Gag(SP2-F1ter), NL4-3*/Gag-Pol
fuse/PR
P1ter (Gag-
Pol(PR-P1ter)), NL4-3*/Gag-Pol
fuse/PR
D25A/RT
P1ter (Gag-Pol(PR-D25A)(RT-P1ter)), NL4-3*/Gag-Pol
fuse/PR
D25A/p15
Y1ter (Gag-Pol(PR-D25A)(p15-Y1ter)),
and NL4-3*/Gag-Pol
fuse/PR
D25A/IN
F1ter (Gag-Pol(PR-D25A)(IN-F1ter)), respectively. The upper line corresponds to the full-length p55 Gag protein,
which contains p6, and is the only Gag-containing protein expressed by NL4-3*/TF
ter. Gag* refers to the region of Gag shared by both Gag and Gag-
Pol that lacks p6. (B) Anti-Gag immunoblots of cell and virus lysates generated from 293T cells transfected with the same proviruses. Bar graph shows
the average +/21 standard deviation from three trials. A single star refers to a p value of less than 0.05; three stars refers to a p value of less than
0.0005.
doi:10.1371/journal.pone.0029421.g003
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PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e29421has a significant impact on how certain empirical observations
should be interpreted. In short, the discovery of inhibitory budding
signals in HIV is altering our view of the cis-acting elements that
drive HIV budding, away from the p6-dependent model of HIV
budding, and towards the EMV-based model of HIV budding.
Materials and Methods
Cell culture and DNA transfection
293T (CRL-11268) cells were obtained from The American
Type Culture Collection (Manasas, VA, USA). The growth
medium in all experiments was DMEM supplemented with 10%
fetal bovine serum, and growth conditions were 37uC, 5% CO2,
and 90–100% humidity. Prior to transfection, 293T cells were
released from the plate by incubation in a 0.05% tryspin/EDTA
solution (Gibco/BRL, Bethesda MD, USA), pelleted by centrifu-
gation at 2006g, and resuspended in growth medium at 7.5610
5
cells/ml. Transfection was carried out by combining DNA (10 mg
total, unless otherwise stated) and 500 mls of the cell suspension in
a 4 mm gap electroporation cuvette, and then electroporating the
cells at 24 ohms, 300 volts, and capacitance of 800 uF, using a
BTX ECM 600 electroporator (Harvard Apparatus, Holliston,
MA). Following electroporation, the cells were resuspended in
10 mls of growth medium, plated on 10 cm tissue culture dishes,
and grown in the incubator for an additional two days.
Plasmids
The HIV proviruses pNL4-3-DE-GFP (pNL4-3*) and NL4-3*/
TF
ter were described previously [15,29]. To generate the mutant
proviruses pNL4-3*/Gag-Pol
fuse, pNL4-3*/Gag-Pol
fuse/PR
D25A,
pNL4-3*/NC
F56ter, pNL4-3*/Gag-Pol
fuse/PR
P1ter and pNL4-3*/
Gag-Pol
fuse/PR
D25A/RT
P1ter we first amplified the internal ApaI-
SbfI fragment of pNL4-3-DE-GFP [29] using sets of nested
primers designed to introduce the desired mutations (Table 1).
Next, each amplified fragment was cleaved with ApaI and SbfI
and inserted between the Apa I and Sbf I sites of pNL4-3-DE-
GFP. The pNL4-3*/Gag-Pol
fuse/PR
D25A/p15
Y1ter and pNL4-3*/
Gag-Pol
fuse/PR
D25A/IN
F1ter proviruses were created by amplify-
ing the internal AgeI-EcoRI fragment from pNL4-3-DE-GFP [29]
using nested sets of primers designed to introduce the desired
mutations, followed by cleaving the amplified products with AgeI
and EcoRI and inserting them into the AgeI and EcoRI sites of
pNL4-3*/Gag-Pol
fuse/PR
D25A. All amplified regions of the
plasmids were sequenced, and experiments were only performed
using clones possessing the desired sequence. The relevant
mutations in these proviruses are shown in a limited sequence
alignment (Table 1).
Virus preparations, antibodies, and immunoblot
Cell and virus lysates were performed essentially as described
[15]. In brief, 293T cells were incubated for two days, followed by
collection of the tissue culture supernatant, and washing of cells
once in DMEM. Cells were then lysed by the addition of SDS-
PAGE sample buffer. To isolate HIV particles, the tissue culture
supernatant was first subjected to centrifugation at 5,0006 g for
15 minutes. The pellet was discarded and the resulting superna-
tant was passed through a sterile, 0.22 micrometer filter. The
filtered supernatant was then spun at 10,0006 g for 30 minutes,
the pellet was discarded, and the supernatant was again spun at
10,0006 g for 30 minutes. The pellet was discarded and the
resulting supernatant was spun at 70,0006 g for 60 minutes to
pellet HIV particles. The supernatant was discarded and the virus-
Table 1. Primers used.
primer name primer sequence
FGag-Pol-ApaI 59-CAAAAATTGCAGGGCCCCTAGG-39
RGag-Pol-SbfI 59- TTTAACCCTGCAGGATGTGG-39
RpGag-Pol 59- AGATCTTCCCTTAAAAAATTAGCCTGTCTC-39
FpGag-Pol 59- GCTAATTTTTTAAGGGAAGATCTGGCC-39
RpNL-TF-F1T 59- CTTCCCTAATTAATTAGCCTGTCTCTCAGTACAATC -39
FpNL-TF-F1T 59- GAGACAGGCTAATTAATTAGGGAAGATCTGG-39
RpNL-PR-P1T 59- CACCTGCAGGTTAGAAGCTAAAGGATACAGTTCCTTG-39
RpNL-RT-P1T 59- CACCTGCAGGTTAAAAATTTAAAGTGCAGCCAATCTG-39
FGag-Pol-AgeI 59- GATTCTAAAAGAACCGGTACATG-39
RGag-Pol-EcoRI 59- CAGTTGTTGCAGAATTCTTATTATG-39
RpNL-p15-Y1T 59- CTTTTCCATGTGTTAGAAAGTTTCTGCTCCTATTATGG-39
FpNL-p15-Y1T 59- CAGAAACTTTCTAACACATGGAAAAGATTAGTAAAAC-39
RpNL-IN-F1T 59- CTTTTCCATGTGTTATAGTACTTTCCTGATTCCAGCAC-39
FpNL-IN-F1T 59- GGAAAGTACTATAACACATGGAAAAGATTAGTAAAAC -39
doi:10.1371/journal.pone.0029421.t001
Figure 4. Expression of Gag-Pol inhibits HIV budding. (A) Line diagram of the Gag and Gag-Pol proteins expressed by NL4-3*/TF
ter and NL4-
3*/Gag-Pol
fuse/PR
D25A, respectively. The upper line corresponds to the full-length p55 Gag protein, which contains p6, and is the only Gag-containing
protein expressed by NL4-3*/TF
ter. Gag* refers to the region of Gag shared by both Gag and Gag-Pol, a region that lacks p6. (B) Anti-Gag
immunoblots of cell and virus lysates generated from 293T cells co-transfected with different amounts of the proviruses NL4-3*/TF
ter and NL4-3*/Gag-
Pol
fuse/PR
D25A. The line graph shows the average +/21 standard deviation from three separate trials. (C) Anti-Gag immunoblots of cell and virus
lysates generated from 293T cells transfected with the proviruses NL4-3* and NL4-3*/TF
ter. Bar graph shows the average +/21 standard deviation
from three trials. A single star refers to a p value of less than 0.05.
doi:10.1371/journal.pone.0029421.g004
Gag-Pol Is an Inhibitor of HIV Budding
PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e29421containing pellet was lysed by resuspension in SDS-PAGE sample
buffer.
For immunoblot experiments, cell and virus lysates (in all cases,
a 1:20 ratio of cell and virus lysates) were separated by SDS-
PAGE, transferred to PVDF membranes, and processed for
immunoblot using specific primary antibodies to HIV Gag CA
domain (mouse anti-Gag monoclonal antibody (3537), AIDS
Research & Reference Reagent Program (NIAID, NIH) and
HRP-linked secondary antibodies (Jackson Immunoresearch, West
Grove, PA, USA)). Gag CA-containing proteins were detected by
chemiluminescent exposure of X-ray film and developed films
were digitally scanned and converted to TIFF files using Adobe
Photoshop CS2 and all images were assembled in Adobe
Illustrator CS2. Protein band intensities were determined using
ImageJ software and these data were used to determine the
budding efficiency (vesicle-associated signal/(vesicle-associated +
cell-associated signals)) of each virus. Relative budding was
determined by comparing the budding of each test virus to that
of a control, which was assigned an arbitrary value of 1. The
statistical analysis of relative budding included the calculation of
averages, standard deviations, and the calculation of p values
(Student’s t test).
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